NASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free VIGL Stock Alerts $3.41 +0.21 (+6.56%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.19▼$3.4150-Day Range$2.68▼$3.4852-Week Range$2.53▼$11.11Volume79,539 shsAverage Volume112,542 shsMarket Capitalization$125.76 millionP/E RatioN/ADividend YieldN/APrice Target$17.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Vigil Neuroscience alerts: Email Address Vigil Neuroscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside410.3% Upside$17.40 Price TargetShort InterestBearish7.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 25 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.51) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector492nd out of 938 stocksBiological Products, Except Diagnostic Industry80th out of 149 stocks 3.3 Analyst's Opinion Consensus RatingVigil Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.40, Vigil Neuroscience has a forecasted upside of 410.3% from its current price of $3.41.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.64% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Vigil Neuroscience has recently increased by 16.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIGL. Previous Next 3.0 News and Social Media Coverage News SentimentVigil Neuroscience has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Vigil Neuroscience this week, compared to 1 article on an average week.Search Interest4 people have searched for VIGL on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.45% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.51) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Sock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About Vigil Neuroscience Stock (NASDAQ:VIGL)Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More VIGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIGL Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL) Lowered by AnalystMarch 29, 2024 | americanbankingnews.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Expected to Post Q1 2024 Earnings of ($0.58) Per ShareMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | americanbankingnews.comVigil Neuroscience (NASDAQ:VIGL) Receives Buy Rating from HC WainwrightMarch 28, 2024 | americanbankingnews.comAnalysts Offer Predictions for Vigil Neuroscience, Inc.'s FY2028 Earnings (NASDAQ:VIGL)March 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vigil Neuroscience’s Advancing TREM2 Programs and Strong Financial PositionMarch 26, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | msn.comVigil Neuroscience GAAP EPS of -$0.57 in-lineMarch 26, 2024 | benzinga.comVigil Neuroscience: Q4 Earnings InsightsMarch 26, 2024 | investorplace.comVIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023March 26, 2024 | globenewswire.comVigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 24, 2024 | finance.yahoo.comIs Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?March 20, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerMarch 20, 2024 | seekingalpha.comVigil Neuroscience appoints Kaufmann as Chief Medical OfficerMarch 20, 2024 | markets.businessinsider.comVigil Neuroscience Appoints Petra Kaufmann As CMOMarch 20, 2024 | globenewswire.comVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerMarch 16, 2024 | seekingalpha.comVIGL Vigil Neuroscience, Inc.March 13, 2024 | globenewswire.comVigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingMarch 12, 2024 | globenewswire.comVigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysMarch 6, 2024 | globenewswire.comVigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024February 29, 2024 | globenewswire.comVigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024February 22, 2024 | benzinga.comVigil Neuroscience Stock (NASDAQ:VIGL) Insider TradesFebruary 7, 2024 | finance.yahoo.comVigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)January 4, 2024 | finanznachrichten.deVigil Neuroscience, Inc.: Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesSee More Headlines Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIGL CUSIPN/A CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Target$17.40 High Stock Price Target$24.00 Low Stock Price Target$4.00 Potential Upside/Downside+410.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.26% Return on Assets-49.50% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio13.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book0.64Miscellaneous Outstanding Shares36,880,000Free Float23,876,000Market Cap$125.76 million OptionableNot Optionable Beta1.80 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Ivana Magovcevic-Liebisch J.D. (Age 57)Ph.D., President, CEO & Director Comp: $908.25kMs. Jennifer Ziolkowski CPA (Age 50)Chief Financial Officer Comp: $617.55kSharon MoraniSenior Director of Facilities & OperationsKelly Neelon Ph.D.Vice President of CMC & Technical OperationsDr. David Gray Ph.D. (Age 49)Chief Scientific Officer Ms. Leah GibsonVice President of Investor Relations and Corporate CommunicationsMr. Christopher Verni J.D. (Age 49)General Counsel & Corporate Secretary April Effort M.B.A.M.S., VP & Head of Corporate DevelopmentMr. Evan A. Thackaberry DABT (Age 51)Ph.D., Senior VP & Head of Early Development Christian Mirescu Ph.D.VP & Head of NeuroimmunologyMore ExecutivesKey CompetitorsAthira PharmaNASDAQ:ATHACEL-SCINYSE:CVMZura BioNASDAQ:ZURAProtalix BioTherapeuticsNYSE:PLXOutlook TherapeuticsNASDAQ:OTLKView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 5,231 shares on 3/11/2024Ownership: 2.227%Goldman Sachs Group Inc.Sold 61,102 shares on 3/1/2024Ownership: 0.237%Citadel Advisors LLCSold 4,211 shares on 2/15/2024Ownership: 6.026%Vanguard Group Inc.Bought 5,231 shares on 2/15/2024Ownership: 2.228%Barclays PLCBought 19,205 shares on 2/15/2024Ownership: 0.345%View All Insider TransactionsView All Institutional Transactions VIGL Stock Analysis - Frequently Asked Questions Should I buy or sell Vigil Neuroscience stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIGL shares. View VIGL analyst ratings or view top-rated stocks. What is Vigil Neuroscience's stock price target for 2024? 5 brokers have issued twelve-month price targets for Vigil Neuroscience's shares. Their VIGL share price targets range from $4.00 to $24.00. On average, they anticipate the company's stock price to reach $17.40 in the next year. This suggests a possible upside of 410.3% from the stock's current price. View analysts price targets for VIGL or view top-rated stocks among Wall Street analysts. How have VIGL shares performed in 2024? Vigil Neuroscience's stock was trading at $3.38 on January 1st, 2024. Since then, VIGL stock has increased by 0.9% and is now trading at $3.41. View the best growth stocks for 2024 here. When is Vigil Neuroscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VIGL earnings forecast. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an IPO on Friday, January 7th 2022. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. Who are Vigil Neuroscience's major shareholders? Vigil Neuroscience's stock is owned by many different institutional and retail investors. Top institutional investors include Citadel Advisors LLC (6.03%), Vanguard Group Inc. (2.23%), Vanguard Group Inc. (2.23%), Sphera Funds Management LTD. (1.49%), Northern Trust Corp (0.39%) and Bridgeway Capital Management LLC (0.37%). Insiders that own company stock include Christopher Verni, Clay Thorp, Evan Thackaberry, Ivana Magovcevic-Liebisch and Spyros Papapetropoulos. View institutional ownership trends. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIGL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.